Savolitinib
- Generic Name
- Savolitinib
- Drug Type
- Small Molecule
- Chemical Formula
- C17H15N9
- CAS Number
- 1313725-88-0
- Unique Ingredient Identifier
- 2A2DA6857R
- Background
Savolitinib has been used in trials studying the treatment and health services research of Tumor, Food Effect, Gastric Cancer, Health Subjects, and Colorectal Cancer, among others.
- Indication
用于含铂化疗后疾病进展或不耐受标准含铂化疗的、具有间质-上皮转化因子（MET）外显子14跳变的局部晚期或转移性非小细胞肺癌成人患者。
Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2019-05-10
- Last Posted Date
- 2025-01-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 247
- Registration Number
- NCT03944772
- Locations
- 🇸🇪
Research Site, Stockholm, Sweden
A Pharmacokinetic and Bioequivalence Study of Savolitinib Tablets in Healthy Chinese Male Volunteers
- Conditions
- Bioequivalence
- Interventions
- First Posted Date
- 2019-03-04
- Last Posted Date
- 2019-05-16
- Lead Sponsor
- Hutchison Medipharma Limited
- Target Recruit Count
- 36
- Registration Number
- NCT03860948
- Locations
- 🇨🇳
Shanghai Xuhui District Central Hospital, Shanghai, Shanghai, China
Precision Immuno-Oncology for Advanced Non-small Cell Lung Cancer Patients With PD-1 ICI Resistance
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2019-02-07
- Last Posted Date
- 2024-05-03
- Lead Sponsor
- Assistance Publique Hopitaux De Marseille
- Target Recruit Count
- 114
- Registration Number
- NCT03833440
- Locations
- 🇫🇷
Assistance Publique Hopitaux de Marseille, Marseille, France
Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib
- Conditions
- Carcinoma
- Interventions
- First Posted Date
- 2018-12-19
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 367
- Registration Number
- NCT03778229
- Locations
- 🇻🇳
Research Site, Ho Chi Minh, Vietnam
Volitinib in Treating Patients With Recurrent or Refractory Primary CNS Tumors
- Conditions
- Refractory Primary Central Nervous System NeoplasmRecurrent Diffuse Intrinsic Pontine GliomaRecurrent Malignant GliomaRecurrent MedulloblastomaRecurrent Primary Central Nervous System NeoplasmRefractory Diffuse Intrinsic Pontine GliomaRefractory Malignant GliomaRefractory Medulloblastoma
- Interventions
- Procedure: Biospecimen CollectionProcedure: Magnetic Resonance ImagingProcedure: X-Ray Imaging
- First Posted Date
- 2018-07-26
- Last Posted Date
- 2025-04-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 41
- Registration Number
- NCT03598244
- Locations
- 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Lucile Packard Children's Hospital Stanford University, Palo Alto, California, United States
🇺🇸Children's Hospital Colorado, Aurora, Colorado, United States
Savolitinib in Treating Patients With MET Amplified Metastatic or Unresectable Colorectal Cancer
- Conditions
- Stage IIIB Colon Cancer AJCC v8Stage IIIC Colon Cancer AJCC v8Stage IVB Colon Cancer AJCC v8Metastatic Rectal AdenocarcinomaStage III Colon Cancer AJCC v8Stage IVA Colon Cancer AJCC v8Stage IVC Colon Cancer AJCC v8Stage IVC Rectal Cancer AJCC v8Unresectable Rectal AdenocarcinomaStage IIIC Rectal Cancer AJCC v8
- Interventions
- First Posted Date
- 2018-07-19
- Last Posted Date
- 2023-10-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 5
- Registration Number
- NCT03592641
- Locations
- 🇺🇸
Los Angeles County-USC Medical Center, Los Angeles, California, United States
🇺🇸USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
Prostate Cancer Biomarker Enrichment and Treatment Selection
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2017-12-28
- Last Posted Date
- 2025-03-17
- Lead Sponsor
- Canadian Cancer Trials Group
- Target Recruit Count
- 200
- Registration Number
- NCT03385655
- Locations
- 🇨🇦
BCCA - Vancouver Cancer Centre, Vancouver, British Columbia, Canada
🇨🇦Saskatoon Cancer Centre, Saskatoon, Saskatchewan, Canada
🇨🇦Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada
Savolitinib vs. Sunitinib in MET-driven PRCC.
- Conditions
- Protein Kinase InhibitorsCarcinomaCarcinoma, Renal CellEnzyme InhibitorsUrologic NeoplasmsKidney DiseasesKidney NeoplasmsNeoplasms by Site
- Interventions
- First Posted Date
- 2017-03-27
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 60
- Registration Number
- NCT03091192
- Locations
- 🇺🇦
Research Site, Sumy, Ukraine
A Phase II Study of HMPL-504 in Lung Sarcomatoid Carcinoma and Other Non-small Cell Lung Cancer
- First Posted Date
- 2016-09-13
- Last Posted Date
- 2021-11-30
- Lead Sponsor
- Hutchison Medipharma Limited
- Target Recruit Count
- 76
- Registration Number
- NCT02897479
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China
🇨🇳Beijing Cancer Hopspital, Beijing, Beijing, China
MEDI4736 Combinations in Metastatic Renal Cell Carcinoma
- Conditions
- Renal Clear Cell CarcinomaRenal Papillary Cell Carcinoma
- Interventions
- First Posted Date
- 2016-06-30
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- Queen Mary University of London
- Target Recruit Count
- 69
- Registration Number
- NCT02819596
- Locations
- 🇬🇧
Thomas Powles, London, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.